top of page


Drug Science Consultancy provides research advice and consultancy services to businesses, governments and other stakeholders on all drug related areas, with particular emphasis on the emerging cannabis and psychedelic medicine markets.

We are a separate, commercially oriented trading arm of the Drug Science charity, and all profits are returned to the charity to support its charitable objectives.

A packet of pills over a diagram of molecules

Our Expertise

We have extensive experience across a range of scientific disciplines and research and development approaches. Our team includes experts in epidemiology, quantitative and qualitative methods, pharmacology, neuroscience and neuroimaging, as well as clinical trial design. In addition, we understand the regulatory landscape for cannabis and psychedelics, and we can provide guidance on navigating these complex bureaucratic processes.

Drug Science Consultancy is committed to providing the highest quality research advice and consultancy services. We work with our clients to ensure that their research is well-designed, ethical, and compliant with all relevant regulations. We also provide regular updates on progress and make ourselves available to answer questions.


We are working together with a trusted group of Contract Research Organisations and have established partnerships with the leading academic institutions in the UK as well as a range of external experts globally.

What we offer

Project Management

Our team will systematically assess the boundaries, objectives, requirements, and deliverables of projects. These foundations give clients a clear understanding of what the project can achieve and how it will be executed. This will often include gathering information about the issue that your project seeks to address, existing solutions, risks, feasibility, budget, and timelines.

Clinical Trial Development

We conduct narrative and systematic reviews to identify studies relevant to your research and development needs. The literature review can be used to identify gaps in knowledge and to inform the design of future research.

Communications and Marketing

We write up scientific or regulatory results based on data emerging from your research. This can be in the form of reports, academic publications, or even social media posts.

Our Experts

Prof David Nutt

Founder and Chief Scientific Officer of Drug Science, David is the Edmond J. Safra Professor of Neuropsychopharmacology and Head of the Centre for Psychedelic Research, at Imperial College London. One of the world’s leading researchers on drugs, David continues to fight for evidence-based drug policies.

Prof Mike Barnes

Mike is Chief Medical Officer at Drug Science, a consultant neurologist, as well as Founder Chair of the Medical Cannabis Clinicians Society, Chair of the Cannabis Industry Council and Chair of Maple Tree Med Can Consultancy. A global medical cannabis expert, Mike has dedicated his career to the development of neurological rehabilitation and medical cannabis treatments and education.

Prof Michael Lynskey

Michael is Chief Research Officer at Drug Science and has previously worked as an academic researcher in mental health and drug science in Australia, the US and UK. He is an epidemiologist and research methodologist and has extensive experience running studies including cross-sectional studies, prospective observational studies of general population and clinic samples, genetically informed and real world data.

Dr Anne Katrin Schlag

Long standing Head of Research and currently CEO of Drug Science, Anne is a Chartered Psychologist, with extensive experience in both qualitative and quantitative drug research, especially medical cannabis and medical psychedelics. Anne holds honorary senior positions at both King’s College London and Imperial College London.

Dr Hannah Thurgur

Hannah is Senior Researcher at Drug Science. Hannah’s experience ranges across biochemistry, neuroscience, pre-clinical and  clinical research, and she has led research on medical cannabis and psychedelics.

Dr Rayyan Zafar

Rayyan is a Senior Researcher at Drug Science, and postdoctoral fellow at Imperial College London. He has led clinical and neuroscience research in the field of  psychopharmacology, and offers extensive experience in clinical trials, as well as biomedical, psychedelic and cannabis science.

Alkyoni Athanasiou-Fragkouli

Alkyoni is Research Officer at Drug Science, where she is instrumental in data collection and analysis of Project Twenty21 (T21), the UK’s first medical cannabis registry. She is  experienced in large scale project management, stakeholder communications as well as protocol development.

James Bunn

Head of Operations at Drug Science, James is our legal and regulatory consultant with experience in the UK, Canada, Australia, USA, Israel and various EU member states. James contributed to the development of the world’s largest psychedelic Real World Evidence project that utilises medical psilocybin products and is able to advise on law and regulatory pathways.

Why Choose Drug Science Consultancy?

We are global thought leaders in medical cannabis and medical psychedelics research and committed to providing the highest quality research advice and consultancy services. We work with our clients to ensure that their research is well-designed, ethical, and compliant with all relevant regulations. We also provide regular updates on our progress and make ourselves available to answer questions.

Cannabis and mushrooms on a table

Contact Us

Please reach out and get in touch if you represent a company that wants to conduct scientific research. 

We will not answer medical cannabis patient queries, please send these to

Publications and Research

Conducting Research

We have extensive experience in conducting different types of qualitative research including interviews, focus groups, content analyses, and media analyses amongst others. These approaches are especially important when looking at a novel topic or idea to gain a deep knowledge of current developments in the field and to understand public and media perceptions of them.

bottom of page